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ABSTRACT: Severe congenital neutropenia (SCN) is a
rare hematopoietic disorder, with estimated incidence of 1
in 200,000 individuals of European descent, many cases
of which are inherited in an autosomal dominant pattern.
Despite the fact that several causal genes have been iden-
tified, the genetic basis for >30% of cases remains un-
known. We report a five-generation family segregating a
novel single nucleotide variant (SNV) in TCIRG1. There
is perfect cosegregation of the SNV with congenital neu-
tropenia in this family; all 11 affected, but none of the
unaffected, individuals carry this novel SNV. Western
blot analysis show reduced levels of TCIRG1 protein in
affected individuals, compared to healthy controls. Two
unrelated patients with SCN, identified by independent
investigators, are heterozygous for different, rare, highly
conserved, coding variants in TCIRG1.
Hum Mutat 35:824–827, 2014. C© 2014 Wiley Periodicals, Inc.
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Severe congenital neutropenia (SCN) is a hematological condi-
tion characterized by blood neutrophil counts (absolute neutrophil
counts or ANC) < 0.5 × 109/L and recurrent bacterial infections
usually beginning very early in childhood. In 1956, Kostmann de-
scribed an autosomal recessive formof SCN [Kostmann, 1956]. This
recessive form of SCN is now attributable to mutations in HAX1,
a Bcl-2-family-related gene [Carlsson and Fasth, 2001; Klein et al.,
2007]. Much more frequently, SCN is an autosomal dominant dis-
order caused by mutations in ELA2, a gene encoding the protein
neutrophil elastase, an enzyme of the neutrophil’s primary granules
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[Horwitz et al., 1999;Dale et al., 2000]. About 60%of cases of SCN in
the North American population are attributable to ELA2mutations
[Xia et al., 2009]. Mutations in other genes, for example, genes af-
fecting glucose homeostasis (SLC37A4,G6PC3), lysosomal function
(LYST, RAB27A, ROBLD3/p14, AP3B1, VPS13B), ribosomal pro-
teins (SBDS, RMRP), mitochondrial proteins (HAX1, AK2, TAZ),
immune functions (STK4,GFI1,CXCR4), and X-linked (WAS), also
cause neutropenia [Boztug and Klein, 2009]. However, many fam-
ilies with autosomal dominant SCN have no identifiable mutation,
suggesting that other SCN genes exist. We used high-density SNP
chips to detect identity-by-descent (IBD) regions among affected in
a large SCN family, followed by exome sequencing to identify coding
single nucleotide variants (SNVs) in the IBD regions. This strategy
implicates TCIRG1 (MIM# 604592) as a novel SCN gene.
Primary analysis was performed on 18 members of a single
five-generation family of European-American descent ascertained
for neutropenia (ANC < 1.5 × 109/L) and severe neutropenia
(ANC< 0.5× 109/L) utilizingDNA extracted fromperipheral blood
mononuclear cells and saliva (Supp. Fig. S1). In 13 of the affected
individuals, the median ANC was 0.524 × 109/L, with range 0.074–
1.1 × 109/L and six of the 13 had severe neutropenia based on
all available clinical data. For eight unaffected members, the me-
dian was 3.819 × 109/L, with range 2.343–6.5 × 109/L. There were
no family members with congenital anomalies of the heart, lungs,
neurological, gastrointestinal, or urogenital systems and no history
of bone disease, frequent fractures, or hearing loss. Two patients
had prominent hemangiomas that became more prominent during
treatment with granulocyte colony stimulating factor. Genes asso-
ciated with SCN, that is, ELA2,HAX1, G6PC3,WAS, and GFI1, had
been previously sequenced in the index case for this family and no
likely causal variants were identified [Xia et al., 2009].
IBDanalysis, carried out using fast IBD from the software package
BEAGLE 3.3.2 [Browning and Browning, 2011] on SNPs from the
200 K SNP HumanCytoSNP-12 BeadChip, reduced the possible
regions underlying the shared phenotype to chromosomes (chrs.) 3
and 11. The five affected cousins in the lowest generations (IDs 410,
411, 504, 505, and 510) shared regions IBD on chrs. 1, 3, and 11.
The unaffected cousin (ID 412) also shared the region on chr. 1, and
parts of the regions on chr. 3q and 11q. This narrowed the regions
of interest to chr. 3 (between 193801183bp and the q terminus, map
build GRCh37/hg18) and 11 (66842469–76462540 bp).
A search of the exome sequences of IDs 410 and 504 in these
regions on chrs. 3 and 11 led to two genes of interest. Two novel
C© 2014 WILEY PERIODICALS, INC.
Table 1. Novel Missense Variants Detected in Regions of Interest
with GERP > 2
Chr. Position HGVS annotation Ref. Alt Gene AA change GERP
11 67075198 NM 017857.3:c.781G>A; G A SSH3 p.Glu261Lys 3.49
11 67817691 NM_006019.3:c.2206C>A; C A TCIRG1 p.Arg736Ser 3.78
11 71712875 NM 173042.2:c.553T>C; T C IL18BP p.Ser185Pro 2.97
11 75317003 NM_033063.1:c.1166C>G; G C MAP6 p.Ala389Gly 2.48
RS identifiers do not exist for these SNVs at the time of publication. Sites in bold are
those for which both affected individuals carry the minor (Alt) allele.
(no rsID and does not exist in the Exome Variant Server (EVS) at
SeattleSNPs [http://evs.gs.washington.edu/EVS/] as of April 2013)
missense SNVs were shared by these two exome sequenced af-
fected in the genes TCIRG1 and MAP6 on chr. 11 (Table 1). Both
SNVs are conserved across mammals (genome evolutionary rate
profiling (GERP) score > 2) [Adzubei et al., 2010]. However, only
TCIRG1 is expressed in blood tissue (monocytes) [Pontius et al.,
2003] and is directly involved in T-cell activation [Utku et al.,
1998], making it the likely etiological candidate. The TCIRG1 SNV
NM 006019.3:c.2206C>A (ClinVar SCV000120004), which causes
the amino acid change–p.Arg736Ser (Fig. 1A), has a GERP score
of 3.78. Sanger sequencing of 20 members (14 affected and six un-
affected) of this family reveals a perfect segregation of the novel
TCIRG1 SNV with affection status (Fig. 1A). Known congenital
neutropenia genes (ELA2, HAX1, G6PC3, WAS, and GFI1) were
checked for sequence variation that might have been missed by the
earlier Sanger sequencing, and no known causal or novel variation
was shown to be shared among these two affected individuals.
Western blot analysis confirmed a possible deregulatory involve-
ment of TCIRG1 protein in the pathogenesis of neutropenia in
this family. Previous studies have shown that Western blot analysis
from patient-derived cells harboring homozygous mutations in this
gene has undetectable concentrations of TCIRG1 protein products
[Frattini et al., 2000]. TCIRG1, through alternate splicing, gives rise
to two separate proteins: Isoforms (-iso) a and b previously known
as OC-116 and TIRC7, respectively [Heinemann et al., 1999; Frat-
tini et al., 2000; Susani et al., 2004]. TCIRG1-isob lacks the first five
exons of the longer variant, TCIRG1-isoa. We performed Western
blot analysis using lysed peripheral blood mononuclear cells from
three affected individuals of this family and healthy volunteers.
Two different commercially available antibodies against TCIRG1
protein were used. A polyclonal antibody developed against the
N-terminal cytoplasmic domain of human TCIRG1-isoa protein
(Santa Cruz Biotechnology, Dallas, TX) detects reduced amounts
of45 kDa TCIRG1 product fragment in all three individuals har-
boring the ARG736SER mutation, compared to healthy controls
(Fig. 1,B1).Thisprotein fragment ismost likely the shorterTCIRG1-
isob. Amonoclonal antibody raised against the partial recombinant
TCIRG1-isoa 121aa–220aa (Abnova, Taipei City, Taiwan) detects
a distinct protein band at 120 kDa. Presumably, this is the full-
length TCIRG1-isoa protein, with similar expression levels in both
affected individuals and healthy controls (Fig. 1, B2). In addition,
we have performed TCIRG1 transcripts analysis (data not shown)
by RT-PCR using the total RNA from the same source as the WB
analysis and found no alterations in mRNA expression compared to
the controls.
It is unclear how the p.Arg736Ser mutation causes a reduction
of the shorter isoform, but not the longer isoform a. It is possible
that the reduced protein in our patients is one of the not yet fully
characterized novel isoforms of TCIRG1 as previously reported by
Smirnova et al. (2005). Apparently, this missense SNV within exon
18 does not cause any detectable alterations in the TCIRG1 tran-
scripts.However, the changedoes affect theobserved level of protein.
The arginine is changed to serine, amajor shift based on amino acids
molecular size and properties, and this change is located at an evo-
lutionary highly conserved site. It is possible that the reduced levels
of protein is due to posttranslational folding defects of the mutant
protein and subsequent endoplasmic reticulum associated degrada-
tion and elimination [Waters, 2001; Meusser et al., 2005; Ding and
Yin, 2008]. The p.Arg736Ser mutation in this family has never been
reported, either as a variant causal for autosomal recessivemalignant
osteopetrosis (arOP) or associated with neutropenia.
As a follow-up, TCIRG1mutational analysis in 20 unrelated SNC
individuals known to be negative for mutations in the known SCN
genes was conducted by standard PCR amplification using Hot-
StarTaq DNA Polymerase (Qiagen, Inc., Valencia, CA) and custom-
designed primer sets. Products of PCR amplification were purified
with QIAquick PCR Purification Kit (Qiagen, Inc.). The ampli-
cons were sequenced in the forward and reverse directions using
BigDye Terminator V3.1 Cycle Sequencing Kits (Applied Biosys-
tems, Foster City, CA) and a capillary DNA analyzer (Applied
Biosystems). Primer set sequences will be provided upon request.
Two SNVs in two individuals were implicated in SCN based on mi-
nor allele frequency (MAF) and GERP score. The first mutation,
Figure 1. A: Electropherogram depicting TCIRG1 novel mutation (the N above the G nucleotide at position 342 in this electropherogram is
computer-generated error and should be labeled as G). B: Western blot analysis of TCIRG1expression: (1) downregulated levels of 45 kDa TCIRG1
product in PB mononuclear cells of three patients (26%, 49%, 35%, respectively) compared to healthy individual. (2) Identical expression level of
TCIRG1-isoa (n = 3).
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rs139617644:G>A, [described in Sobacchi et al., 2001] is located
in the acceptor splice site of intron 14, and predicted to alter the
splicing (data not shown). This SNV occurs in only three of 12,988
chromosomes in EVS (July 2013), has GERP = 4.12, and is highly
conserved among vertebrates [Siepel et al., 2005]. The second mu-
tation, rs186758849:G>A, causes p.GLY160GLU and is located in
exon 5. This SNV has MAF = 0.006, is predicted to be possibly dam-
aging [Adzhubei et al., 2010], and is highly evolutionarily conserved
(GERP = 4.42). No other SNVs predicted to alter protein structure
were found.
TCIRG1 is located at 11q13, consists of 20 exons, and through
alternate splicing gives rise to two main isoforms: TCIRG1-isoa and
TCIRG1-isob. TCIRG1-isoa is a full-length isoform and encodes
a3 subunit of vacuolar H+-ATPase. TCIRG1-isob is a shorter iso-
form, lacking the first five exons of the longer isoform. Vacuolar
H+-ATPases are well-described large protein complexes composed
of two main functional domains: peripheral V1 and membrane-
associatedV0.Bothdomains consist ofmultiple subunits.V-ATPases
are involved in regulation of the pH of intracellular compartments
and organelles of eukaryotic cells, including the pH of neutrophil
phagocytic vacuoles (Supp. Fig. S2) [Nanda et al., 1996; Yao et al.,
2007; Hinton et al., 2009].
TCIRG1-isoa is highly expressed in osteoclasts and is essential for
bone resorption. Homozygous or compound heterozygous muta-
tions in this gene cause arOPcharacterizedbybone resorptiondefect
due to osteoclastmalfunction through impairing acidification at the
ruffle border interface between osteoclasts and bone [Frattini et al.,
2000]. More than 50% of all cases of arOP are attributable to muta-
tions in TCIRG1, and more than 90 different mutations have been
described.
Although congenital neutropenia due to mutations in TCIRG1
have not been previously described, there is biological evidence
for a role in SCN. Experimental data reveals that arginine 735 in
yeast TCIRG1 protein product (homologous to human ARG736)
is essential for proton translocation [Kawasaki-Nishi et al., 2001].
Studies in mice have shown that although a homozygous muta-
tion at amino acid 740 (homologous to human amino acid 736) is
lethal in mice, a heterozygous mutation of the V-ATPase a3 sub-
unit R740S causes dominant negative osteopetrosis [Ochotny et al.,
2011]. As mentioned above, through an alternative splicing and
usage of an alternative initiation codon in exon 7, TCIRG1 codes
another protein, TIRC7-isob, which is a T-cell-specific membrane
proteindemonstrated toplay anessential role forT-lymphocyte acti-
vation and immune response. RNA interference to silence TCIRG1-
isob, Ap6i +/– mice reduced inflammatory responses in a mouse
model of periodontal disease and decreased osteoclasts and mono-
cytes [Jiang et al., 2013]. However, these reports do not comment
on blood neutrophil counts or granulocytopoiesis in the mice. Al-
though the secondary hematological consequences of osteopetrosis
are well known, there are no comments in the literature on blood
neutrophil counts or granulocytopoiesis in individuals harboring
heterozygous variants in this gene. Interestingly, there are multiple
novel splice variants of TCIRG1 with unknown functional effects
and the proteins are expressed in numerous human tissues (heart,
liver, kidney, lung, andpancreas) [Susani et al., 2004; Smirnova et al.,
2005].
It is possible that TCIRG1 is relevant to SCN through other
pathways. Besides regulating bone resorption, osteoclasts regulate
osteoblasts, a cell population implicated in hematopoietic stem
cell maintenance [Zhang et al., 2002; Calvi et al., 2003]. Indeed,
osteoclast activation has been implicated in the mobilization of
hematopoietic progenitor cells from the bone marrow to blood
[Kollet et al., 2006]. Moreover, prior published studies of RNA pro-
filing of murine osteoblasts indicate that TCIRG1 is also expressed
in this cell population [Eash et al., 2010]. Thus, it is possible that
TCIRG1 p.Arg736Ser may indirectly disrupt granulopoiesis by al-
tering the bone marrow microenvironment. Alternatively, TCIRG1
products are broadly expressed in hematopoietic cells. RNA expres-
sion profiling of granulocytic precursors from healthy donors sug-
gests that TCIRG1-isoa is highly expressed in promyelocytes. Thus,
TCIRG1 p.Arg736Ser may also directly act on granulocytic precur-
sors to impair their differentiation or maturation. Further studies
will be directed to defining the mechanisms for neutropenia and
the importance of the vATPases in maintaining the integrity of the
pathway for neutrophil production and deployment. Understand-
ing the pathogenesis of TCIRG1-associated neutropenia will require
severalmethodological approaches andmore studies involving both
individual patients and families.
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